Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical [sup.177]Lu-DOTA-PSMA

Preclinical Study of Therapeutic Efficacy of a New Russian Radiopharmaceutical [sup.177]Lu-DOTA-PSMA

The therapeutic efficacy of a Russian radiopharmaceutical [sup.177]Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with [sup.177]Lu-DOTA-PSMA were significantly...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bulletin of experimental biology and medicine 2023-12, Vol.172 (2), p.224
Hauptverfasser: Tishchenko, V.K, Vlasova, O.P, Lebedeva, A.A, Fedorova, A.V, Pankratov, A.A, Morozova, N.B, Kuzenkova, K.A, Stepchenkova, E.D, Shegai, P.V, Ivanov, S.A, Kaprin, A.D
Format: Artikel
Sprache:eng
Schlagworte:
Antigens
Drug approval
Drug therapy
Health aspects
Prognosis
Prostate cancer
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The therapeutic efficacy of a Russian radiopharmaceutical [sup.177]Lu-DOTA-PSMA was studied in vivo using male BALB/c nu/nu (nude) mice with prostate carcinoma 22Rv1 xenografts by tumor growth inhibition criterion. The mean tumor volumes in mice treated with [sup.177]Lu-DOTA-PSMA were significantly lower than in animals of the control group. There were no significant differences in the values of tumor growth inhibition between the groups of animals receiving 3.7 or 7.4 MBq of [sup.177]Lu-DOTA-PSMA. Key Words: prostate-specific membrane antigen; metastatic castrate-resistant prostate cancer; radioligand therapy; lutetium-177; radiopharmaceutical
ISSN:0007-4888
DOI:10.1007/s10517-024-05999-z